OCX 410
Alternative Names: Anti-Chi3l1/PD-1 bi-specific antibodies; Anti-Chi3l1/PD-1 bi-specific mAb; OCX-410Latest Information Update: 06 Oct 2023
At a glance
- Originator Brown University
- Developer Ocean Biomedical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Glycoprotein inhibitors; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer